Skip to content

Abstract A041: KRAS inhibition drives adaptive surfaceome remodeling and reveals ALPP/ALPPL2 as a targetable vulnerability in pancreatic cancer

Sep 2026 · Cancer Research · 0 citations

TL;DR

These studies establish a comprehensive proteomic resource for the PDAC/KRASi research community and identify ALPP/ALPPL2 as a promising cell surface target for combination with KRASi to drive deeper, sustained responses and prevent or forestall KRASi resistance.

Abstract

KRAS is the dominant oncogene in pancreatic ductal adenocarcinoma (PDAC), mutated in ∼90% of tumors, and required for tumor initiation and tumor maintenance. The overall 5-year survival rate of PDAC remains a dismal ∼10%, underscoring an unmet need to develop novel therapies to ultimately improve patients’ outcomes. While recent mutant allele-specific (KRASi) and pan-RAS inhibitors (RASi) demonstrate unprecedented activity in PDAC patients in clinical trials, genetic and non-genetic mechanisms of intrinsic and treatment-induced resistance limit the long-term efficacy of single-agent RAS/KRASi strategies. We performed quantitative temporal KRASi global, phosphoproteome, and surfaceome proteomics to comprehensively identify non-genetic adaptive pathways and cell surface biomarkers in response to acute and long-term KRAS inhibition in in vitro and in vivo models of PDAC. Global proteomics demonstrated acute suppression of KRAS-dependent proliferative and hallmark MYC and cell-cycle programs that rebounded by 7 days despite continued treatment. Resistant cells underwent large-scale proteomic reprogramming, marked by heterogeneous pathway enrichment and a consistent enrichment of lysosomal biogenesis pathways. Phosphoproteomics and kinase-substrate network analysis identified compensatory activation of RHO GTPase-associated kinases, Aurora kinase B, and PAK family kinases as adaptive responses to KRAS inhibition. Surfaceome profiling captured over 700 dysregulated cell surface proteins across timepoints, including known clinical targets such as TACSTD2, MUC1, and SLC44A4, and integration with global proteomics yielded over 1,000 quantified unique surface peptides. Integrating our KRASi-proteome with publicly available datasets, we developed and applied a machine learning algorithm to nominate and rank cell surface targets for combination targeting with KRASi. Among top-scoring hits, Placental Alkaline Phosphatase (ALPP) was validated as upregulated in response to KRASi, with ALPP upregulation mediated by KRASi-induced transcriptional compensatory JAK2/STAT3 signaling, leading to increased surface expression. Axcynsis has developed a novel clinic-ready ALPP/ALPPL2 (ALPG)-targeting antibody-drug conjugate (ADC) with a homogeneous drug-to-antibody ratio (DAR 4) and site-specific MMAE conjugation. This ADC demonstrated single-agent efficacy in in vitro and PDX models of PDAC. When this ADC was combined with KRASi, we observed enhanced internalization in multiple cancer cell lines, synergistic combination efficacy in patient-derived organoids, and anti-tumor efficacy in cell-derived xenografts of PDAC in vivo. Together, these studies establish a comprehensive proteomic resource for the PDAC/KRASi research community and identify ALPP/ALPPL2 as a promising cell surface target for combination with KRASi to drive deeper, sustained responses and prevent or forestall KRASi resistance. Jonathan M. DeLiberty, Fan Yi Kong, Qijia Yu, Nicole Sindoni, Johnson Lin, Kalisa Kang, Elizabeth Y. Kim, Sabrina Chen, Aparna Padhye, Oluwadara Coker, Joshua H. Choe, Joao A. Paulo, Myungsun Shin, Lewis Hendrianto, Kazuki Takahashi, Salome Shubitidze, Tobiloba E. Oni, Shaojun Liu, Bryan K. S. Yeung, Bin Zou, Clint A. Stalnecker, Andrew J. Aguirre, Joseph D. Mancias. KRAS inhibition drives adaptive surfaceome remodeling and reveals ALPP/ALPPL2 as a targetable vulnerability in pancreatic cancer [abstract]. In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_2):Abstract nr A041.

View source

Similar papers

Sep 2026

Abstract B008: Pan-RAS-GTP inhibition disrupts the KRAS-SHH axis to reprogram cancer-associated fibroblast subtypes and reduce stiffness in pancreatic cancer

Oncogenic KRAS mutations are present in ∼95% of pancreatic ductal adenocarcinoma (PDAC) cases and have long been considered undruggable. The recent clinical emergence of RAS inhibitors marks a transformative moment in PDAC therapy, yet their impact on the tumor microenvironment (TME) remains largely unknown. This is...

Marie C. Hasselluhn, Allison C. Hess, L. Tomassoni et al. · 0 citations
#gene editing Sep 2026

Abstract B067: Dissection of the in vitro response landscape in PDAC under KRAS inhibition reveals co-occurring conserved and adaptive transcription programs

In vitro perturbation is used to decipher the early transcriptional response programs in patient-derived 2D and 3D cell models of PDAC to KRAS inhibition and identify a robust RNA-based signature with potential utility for pharmacodynamic monitoring and the study of adaptive resistance.

H. Schürmann, J. Asche, S. Liffers et al. · 0 citations
Sep 2026

Abstract B061: Epigenetic EZH2 dependency in KRAS inhibitor-resistant PDAC cells

The findings uncover an epigenetically-driven resistance mechanism in which EZH2 promotes NE differentiation and provides a bypass signaling under KRAS inhibition, and may represent a promising therapeutic strategy to overcome KRAS inhibitor resistance and improve the clinical outcome for PDAC patients.

G. Outeiro-Pinho, Aref Hosseini, Maciej Garczyk et al. · 0 citations
Sep 2026

Abstract A012: Investigating the heterogeneity of different KRAS point mutations on DRP1 activation and its regulation of the TME in pancreatic cancer

This group identified that DRP1 loss in KRAS-mutant PDAC tumor cells alters mitochondrial shape and reduces glycolysis and cell proliferation in murine models and hypothesize that reliance on DRP1 activation in PDAC is KRAS-mutant-specific and shapes the TME to promote survival.

V. Remley, Varna Selvakumar, Nadiya Harris et al. · 0 citations
Sep 2026

Abstract B087: Impact of RAS inhibition on T cell maturation in the PDAC microenvironment

It is suggested that pharmacologic and genetic KRAS inhibition differentially remodel the intratumoral T cell compartment, whereas both induce similar T cell changes within the liver premetastatic niche.

Lauren Gerbereux, Rashmi Kumar, E. Lasse-Opsahl et al. · 0 citations
Sep 2026

Abstract PR014: Integrated translational analyses of the first generation KRAS G12D degrader setidegrasib identify mechanisms of response and resistance and offers rational combination strategies in pancreatic cancer

KRAS G12D is a prevalent oncogenic driver in PDAC, which has a high unmet need due to few effective targeted therapies. Setidegrasib, a novel KRAS G12D-targeted protein degrader, eliminates the oncogenic driver to suppress downstream signaling and induce tumor cell death. Early clinical activity was reported in a...

W. Park, S. Kadam, A. Kasi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.